Loading...
XSHE
002864
Market cap517mUSD
Dec 05, Last price  
34.90CNY
1D
-2.02%
1Q
18.55%
IPO
119.77%
Name

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd

Chart & Performance

D1W1MN
XSHE:002864 chart
P/E
30.41
P/S
3.76
EPS
1.15
Div Yield, %
0.63%
Shrs. gr., 5y
3.83%
Rev. gr., 5y
9.79%
Revenues
974m
-0.71%
226,614,469245,695,161256,097,405305,425,505376,791,557489,447,811610,636,793670,312,981887,484,877974,293,135980,828,104973,864,163
Net income
120m
+8.91%
32,894,42640,072,40342,638,23139,527,73643,718,97564,681,88471,778,89679,115,00193,169,906101,163,536110,432,177120,271,592
CFO
157m
+50.50%
25,433,84148,555,47540,620,72961,991,43628,449,11346,846,10667,886,53192,238,027116,035,587125,362,160104,047,784156,592,822
Dividend
Jun 03, 20240.22 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd researches and develops, produces, and sells drugs and GAP cultivation of medicinal materials in China. It offers orthopedic, cardio-cerebrovascular, digestive, supplement category, respiratory, Chinese anti-inflammatory, pediatric, gynecology, hepatobiliary, and specialty drugs. The company was founded in 1997 and is headquartered in Xi'an, China.
IPO date
Nov 16, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT